These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

204 related articles for article (PubMed ID: 31009153)

  • 1. Role of cyclin-dependent kinases (CDKs) in hepatocellular carcinoma: Therapeutic potential of targeting the CDK signaling pathway.
    Shen S; Dean DC; Yu Z; Duan Z
    Hepatol Res; 2019 Oct; 49(10):1097-1108. PubMed ID: 31009153
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Activation of cyclin-dependent kinases CDC2 and CDK2 in hepatocellular carcinoma.
    Li KK; Ng IO; Fan ST; Albrecht JH; Yamashita K; Poon RY
    Liver; 2002 Jun; 22(3):259-68. PubMed ID: 12100577
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The use of cyclin-dependent kinase inhibitors alone or in combination with established cytotoxic drugs in cancer chemotherapy.
    Grant S; Roberts JD
    Drug Resist Updat; 2003 Feb; 6(1):15-26. PubMed ID: 12654284
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Predictors of ribociclib-mediated antitumour effects in native and sorafenib-resistant human hepatocellular carcinoma cells.
    Reiter FP; Denk G; Ziesch A; Ofner A; Wimmer R; Hohenester S; Schiergens TS; Spampatti M; Ye L; Itzel T; Munker S; Teufel A; Gerbes AL; Mayerle J; De Toni EN
    Cell Oncol (Dordr); 2019 Oct; 42(5):705-715. PubMed ID: 31250364
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cyclin-dependent protein kinase inhibitors including palbociclib as anticancer drugs.
    Roskoski R
    Pharmacol Res; 2016 May; 107():249-275. PubMed ID: 26995305
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Targeting Cyclin-Dependent Kinases in Ovarian Cancer.
    Zhou Q
    Cancer Invest; 2017 Jul; 35(6):367-376. PubMed ID: 28406716
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cyclin-dependent protein serine/threonine kinase inhibitors as anticancer drugs.
    Roskoski R
    Pharmacol Res; 2019 Jan; 139():471-488. PubMed ID: 30508677
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Investigational drugs targeting cyclin-dependent kinases for the treatment of cancer: an update on recent findings (2013-2016).
    Di Giovanni C; Novellino E; Chilin A; Lavecchia A; Marzaro G
    Expert Opin Investig Drugs; 2016 Oct; 25(10):1215-30. PubMed ID: 27606939
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Novel direct and indirect cyclin-dependent kinase modulators for the prevention and treatment of human neoplasms.
    Senderowicz AM
    Cancer Chemother Pharmacol; 2003 Jul; 52 Suppl 1():S61-73. PubMed ID: 12819936
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The roles and therapeutic potential of cyclin-dependent kinases (CDKs) in sarcoma.
    Liao Y; Feng Y; Shen J; Hornicek FJ; Duan Z
    Cancer Metastasis Rev; 2016 Jun; 35(2):151-63. PubMed ID: 26669603
    [TBL] [Abstract][Full Text] [Related]  

  • 11. An insight into the emerging role of cyclin-dependent kinase inhibitors as potential therapeutic agents for the treatment of advanced cancers.
    Chohan TA; Qayyum A; Rehman K; Tariq M; Akash MSH
    Biomed Pharmacother; 2018 Nov; 107():1326-1341. PubMed ID: 30257348
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Recent advances in the development of selective small molecule inhibitors for cyclin-dependent kinases.
    Hirai H; Kawanishi N; Iwasawa Y
    Curr Top Med Chem; 2005; 5(2):167-79. PubMed ID: 15853645
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The activation of MEK/ERK signaling pathway by bone morphogenetic protein 4 to increase hepatocellular carcinoma cell proliferation and migration.
    Chiu CY; Kuo KK; Kuo TL; Lee KT; Cheng KH
    Mol Cancer Res; 2012 Mar; 10(3):415-27. PubMed ID: 22241220
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cyclin-dependent kinase inhibitors as anticancer drugs.
    Krystof V; Uldrijan S
    Curr Drug Targets; 2010 Mar; 11(3):291-302. PubMed ID: 20210754
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Targeting Cyclin-Dependent Kinases for Treatment of Gynecologic Cancers.
    Lin ZP; Zhu YL; Ratner ES
    Front Oncol; 2018; 8():303. PubMed ID: 30135856
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cancer therapy by cyclin-dependent kinase inhibitors (CDKIs): bench to bedside.
    Hassanzadeh A; Shomali N; Kamrani A; Soltani-Zangbar MS; Nasiri H; Akbari M
    EXCLI J; 2024; 23():862-882. PubMed ID: 38983782
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Hepatocellular Carcinoma: Etiology and Current and Future Drugs.
    Jindal A; Thadi A; Shailubhai K
    J Clin Exp Hepatol; 2019; 9(2):221-232. PubMed ID: 31024205
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Extracellular signal-regulated kinase induces cyclin D1 and Cdk-2 expression and phosphorylation of retinoblastoma in hepatocellular carcinoma.
    Huynh H; Do PT; Nguyen TH; Chow P; Tan PH; Quach TH; Van T; Soo KC; Tran E
    Int J Oncol; 2004 Dec; 25(6):1839-47. PubMed ID: 15547725
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Chinese herbal medicine-derived compounds for cancer therapy: a focus on hepatocellular carcinoma.
    Hu Y; Wang S; Wu X; Zhang J; Chen R; Chen M; Wang Y
    J Ethnopharmacol; 2013 Oct; 149(3):601-12. PubMed ID: 23916858
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Anti-hepatocellular carcinoma activity of the cyclin-dependent kinase inhibitor AT7519.
    Karaś K; Karwaciak I; Chałaśkiewicz K; Sałkowska A; Pastwińska J; Bachorz RA; Ratajewski M
    Biomed Pharmacother; 2023 Aug; 164():115002. PubMed ID: 37311277
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.